Literature DB >> 24704796

Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.

Marcus C Ferguson1, Tultul Nayyar1, Twum A Ansah2.   

Abstract

Clinical observations have suggested that antagonism of 5-HT2A receptors may benefit patients with parkinsonian symptomatology. The mechanism of the antiparkinsonian effects of 5-HT2A receptor antagonists has not been fully elucidated. We have shown that the selective 5-HT2A receptor antagonist M100907 [R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenethyl)]-4-piperidinemethanol] improved motor impairments in mice treated with the parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In Parkinson's disease (PD) patients and animal models of parkinsonism dopamine denervation is associated with increased cortico-striatal glutamatergic transmission. We hypothesized that 5-HT2A receptor antagonists may exert their antiparkinsonian effects by decreasing striatal glutamate. Here, using in vivo microdialysis, we have shown an increased basal level of extracellular striatal glutamate when measured 3weeks after MPTP administration. The local administration of M100907 to the striatum significantly decreased striatal extracellular glutamate levels in MPTP-treated and saline treated mice. Basal extracellular serotonin (5-HT) levels were also elevated, whereas dopamine (DA) levels were significantly reduced in the striatum of MPTP-treated mice. Infusion of M100907 into the striatum produced no effect on dopamine or 5-HT levels. Local application of tetrodotoxin suppressed glutamate, 5-HT and DA concentrations in striatal dialysates in the presence or absence of M100907. The striatal expression of the glutamate transporter GLT1 was unchanged. However, there was an upregulation of the expression of 5-HT2A receptors in the striatum of MPTP-treated animals. Our data provide further evidence of enhanced glutamatergic neurotransmission in parkinsonism and demonstrate that blocking 5-HT2A receptors in the striatum will normalize glutamatergic neurotransmission.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glutamate; M100907; MPTP; Microdialysis; Parkinsonism; Serotonin

Mesh:

Substances:

Year:  2014        PMID: 24704796      PMCID: PMC4059615          DOI: 10.1016/j.neuint.2014.03.016

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  64 in total

1.  Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.

Authors:  Jennifer L Taylor; Christopher Bishop; Thomas Ullrich; Kenner C Rice; Paul D Walker
Journal:  Neuropharmacology       Date:  2006-01-23       Impact factor: 5.250

2.  Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons.

Authors:  N Lindefors; U Ungerstedt
Journal:  Neurosci Lett       Date:  1990-07-31       Impact factor: 3.046

3.  Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway.

Authors:  C A Ingham; S H Hood; B van Maldegem; A Weenink; G W Arbuthnott
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

Review 4.  The mechanism of action of novel antipsychotic drugs.

Authors:  H Y Meltzer
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

Review 5.  ACP-103, a 5-HT2A receptor inverse agonist.

Authors:  Claire Roberts
Journal:  Curr Opin Investig Drugs       Date:  2006-07

6.  Unbiased stereological estimation of the number of neurons in the human hippocampus.

Authors:  M J West; H J Gundersen
Journal:  J Comp Neurol       Date:  1990-06-01       Impact factor: 3.215

7.  Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

Authors:  S M Sorensen; J H Kehne; G M Fadayel; T M Humphreys; H J Ketteler; C K Sullivan; V L Taylor; C J Schmidt
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

8.  The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis.

Authors:  B H Westerink; J Tuntler; G Damsma; H Rollema; J B de Vries
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

Review 9.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.

Authors:  Amanda L Sheldon; Michael B Robinson
Journal:  Neurochem Int       Date:  2007-04-19       Impact factor: 3.921

10.  Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.

Authors:  Carine Chassain; Guy Bielicki; Elodie Durand; Stéphane Lolignier; Fatma Essafi; Amidou Traoré; Franck Durif
Journal:  J Neurochem       Date:  2007-12-13       Impact factor: 5.372

View more
  1 in total

Review 1.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.